1 / 41

Barrett’s Ablation – Who to Rx & What Modality

Barrett’s Ablation – Who to Rx & What Modality. Richard E. Sampliner, MD Southern Arizona VA Health Care System University of Arizona Health Sciences Center Tucson, Arizona. Microscopic Squamous Islands Without Surgery.

valmai
Download Presentation

Barrett’s Ablation – Who to Rx & What Modality

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Barrett’s Ablation – Who to Rx & What Modality Richard E. Sampliner, MD Southern Arizona VA Health Care System University of Arizona Health Sciences Center Tucson, Arizona

  2. Microscopic Squamous Islands Without Surgery • Sampliner RE, Steinbronn K, Garewal HS, et al. Squamous mucosa overlying columnar epithelium in Barrett’s esophagus in the absence of antireflux surgery. Am J Gastroenterol1988;83:510-12 2

  3. 3

  4. Microscopic Squamous Over Columnar Epithelium • 7 of 45 Barrett’s patients • 6 treated with H2RA • Length 0.4 – 1.9mm • One had prior anti-reflux surgery Sampliner, Am J Gastroenterol 1988;83:510 4

  5. Squamous Regrowth • Occurs over intestinal metaplasia • Occurs with medical therapy 5

  6. Squamous Islands With Underlying Intestinal Metaplasia • Sharma P, Morales TG, Bhattacharyya A, Garewal HS, Sampliner RE. Squamous islands in Barrett’s esophagus: what lies underneath? Am J Gastroenterol1998;93:332-35 6

  7. 7

  8. Squamous Islands • 22 Barrett’s patients squamous islands biopsied • 18 on PPI, mean duration 2.3 years • 10 underlying intestinal metaplasia • Not necessarily regression Sharma, Am J Gastroenerol 1998;93:332 8

  9. Partial Regression an Inadequate Endpoint • 58 year old white male with Barrett’s with HGD – • Open fundoplication 7 months later • 60mg lansoprazole daily 16 months later • Esophagectomy 2 years later after acute respiratory failure due to gastric herniation • Extensive squamous re-epithelialization with underlying intramucosal cancer in resection Sampliner, Am J Gastroenerol 1993;88:2092 9

  10. Squamous Repopulation • Can be a cover-up • Goal: No intestinal metaplasia 10

  11. Impact of Prolonged Proton Pump Inhibitor in Barrett’s Esophagus • Sampliner RE. Effect of up to three years of high dose lansoprazole on Barrett’s. Am J Gastroenterol1994;89:1844-48 • Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH with high dose proton pump inhibitor therapy does not result in regression of Barrett’s esophagus. Am J Gastroenterol 1997;92:582-85 11

  12. High Dose PPI • 27 long segment Barrett’s • 60mg lansoprazole daily • Mean follow-up 2.9 years • Mean length 5.7+2.3 to 5.3+2.3cm • 6 squamous islands at baseline, 20 at final visit Sampliner, Am J Gastroenterol 1994;89:1844 12

  13. Normalization of Esophageal pH With PPI • 8 of 13 patients on 60mg lansoprazole • Mean pH <4 0.8% • Mean length baseline 5.6cm, at 5.7 years 5.0cm • Even normal esophageal pH over an extended period does not eliminate Barrett’s Sharma, Am J Gastroenterol 1997;92:582 13

  14. Incidence of Adenocarcinoma • Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett’s esophagus – a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol1997;92:212-15 14

  15. Incidence of Adenocarcinoma – 170 Barrett’s Patients Followed 4.8 Years • Prevalence cancers 4% • Incidence – 0.5% per year, 1/208 patient years • Mean age 62, 98% male • Prior estimates up to 2% Drewitz, Am J Gastroenterol 1997;92:212 15

  16. Definition of Barrett’s Esophagus • Sharma P, Morales TG, Bhattacharyya A, Garewal HS, Sampliner RE. Dysplasia in short segment Barrett’s esophagus – a prospective 3 year follow up. Am J Gastroenterol1997;92:2012-16 • Sharma P, Morales TG, Sampliner RE. Short segment Barrett’s esophagus: the need for standardization of the definition and of endoscopic criteria. Am J Gastroenterol1998;93:1033-36 • Sharma P, Weston AP, Morales T, Topalovski M, Mayo MS, Sampliner RE. Relative risk of dysplasia for patients with intestinal metaplasia in the distal oesophagus and the gastric cardis. Gut2000;46:9-13 16

  17. Barrett’s Esophagus - Diagnosis Barrett’s Esophagus - Diagnosis Columnar-appearing distal esophagus Intestinal metaplasia Sampliner RE, Am J Gastroenterol 2002; 97:1888 17

  18. Proposed Classification of Intestinal Metaplasia TerminologyLength Adenocarcinoma Surveillance RiskRecommended LSBE >3cm Yes Yes SSBE <3cm Yes Yes Gastric cardia IM Unclear No Sharma, Am J Gastroenterol 1998;93:1033 18

  19. Endoscopic Reversal of Barrett’s Esophagus • Sampliner RE, Hixson LJ, Fennerty MB, Garewal HS. Regression of Barrett’s esophagus by laser ablation in an anacid environment. Dig Dis Sci1993;38:365-68 • Sharma P, Jaffe PE, Bhattacharyya A, Sampliner RE. Durability of new squamous epithelium following endoscopic reversal of Barrett’s esophagus. Gastrointest Endosc1999;50:159-64 • Sampliner RE, Faigel D, Fennerty MB, et al. Effective and safe endoscopic reversal of nondysplastic Barrett’s esophagus with thermal electrocoagulation combined with high dose acid inhibition: a multicenter study. Gastrointest Endosc2001;53:554-58 19

  20. Hypothesis for Reversal • Metaplasia result of squamous injury with replacement by abnormal differentiation of esophageal stem cell • Decrease acid and refluxate, reinjure Barrett’s epithelium new squamous repopulation Sampliner, Dig Dis Sci 1993;38:365 20

  21. PPI + MPEC • 58 patients with 2-6cm Barrett’s • 40mg omeprazole bid • 6 month post treatment follow-up • 4-quadrant large capacity biopsy every 2cm • No endoscopic Barrett’s – 85% • No endoscopic or histologic – 78% Sampliner, Gastrointest Endosc 2001;53:554 21

  22. MPEC 22

  23. New Squamous DurabilityPost Reversal • 11 patients, Barrett’s 4.4cm, omeprazole 49mg/d • Mean 36 month F/U • 7 with interval intestinal metaplasia,½ of times sampled Sharma, Gastrointest Endosc 1999;50:159 23

  24. Two Year Durability (IM) - ITT

  25. Esophageal Adenocarcinoma & Other Malignancies Pohl, JNCI 2005;97:142 25

  26. Esophageal Adenocarcinoma • Lethal • All patients 5 year survival 13% • Most present with advanced, non-curable disease Eloubeide, Am J Gastroenterol 2003;98:627 26

  27. Long-Term Survival: Endoscopic & Surgical Therapy of HGD in Barrett’s EMR+PDT Esophagectomy n 129 70 *F/U (mo) 65 60 (p.008) Mortality 9% 8.5% *BE length 5 7 (.003) Cardiac disease 30 14 (.015) Comorbidity 2 0 (<.0001) Wang, Gastroenterology 2007;132:1226 27

  28. Cancer Free Survival in the PDT and Surgical Groups Wang, Gastroenterology 2007;132:1226 28

  29. 29

  30. 30

  31. EMR • Excellent specimens • True T staging • Therapeutic role 31

  32. 32

  33. Results Baseline Demographics “Two Year Efficacy Group” 11 patients (22%) had focal RFA at 15 mo per protocol for uneven z-line (not histology-based). No further RFA was allowed unless prior visit histology demonstrated IM (n=3). 33

  34. Two Year Durability (IM) - ITT

  35. RFA Safety – n=119 • SAE: 4 (3.4%) • 1 bleed, 3 admitted for chest pain (24 hr) • Strictures: 9 (7.6% per patient, 1.9% per case) • 6 after circumferential RFA, 3 after focal RFA • 3/9 had stricture prior to RFA • All resolved with median of 1.5 dilations

  36. Endoscopic Ablation – Decision Making Adapted from Wang KK, 2004 36

  37. Planning Endoscopic Therapy for Barrett’s Esophagus 37

  38. Ablation Techniques • Argon plasma coagulation • Cryotherapy • Endoscopic resection • Multipolar electrocoagulation • Photodynamic therapy • Radio-frequency ablation 38

  39. Barrett’s Reversal • Goal: No endoscopic abnormal lining No intestinal metaplasia – sampling a problem • New squamous is durable • Can be done safely • Who should be reversed? 39

  40. Target Lesions for Endoscopic Therapy • High-grade dysplasia • Intramucosal adenocarcinoma 40

More Related